Neuronetics, Inc. (STIM)

Neuronetics, Inc.'s stock price has experienced significant fluctuations over the past six months, including a 65.29% decrease over the last six months and a 55.73% decrease in the last month as of November 25, 2025. Key events impacting the stock include the Q3 2025 earnings release, which reported revenue growth but a net loss, the acquisition of Greenbrook TMS, which is driving high treatment volumes, an increase in Q2 sales, updated 2024 financial results revising figures related to the Greenbrook TMS acquisition, and analyst ratings with a potential upside of 121.84% despite the stock trading below its moving averages.

While no explicit information on demand seasonality for Neuronetics, Inc.'s products and services was found, the company has demonstrated consistent revenue growth driven by increasing adoption of NeuroStar therapy. Strong growth in adolescent new patient starts in the first half of 2025, influenced by expanded insurance coverage, suggests a relatively stable and growing demand rather than pronounced seasonal fluctuations.

Neuronetics, Inc. is a commercial-stage medical technology company focused on products that improve the lives of patients with psychiatric and neurohealth disorders. Their main product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation (TMS) to treat major depressive disorder (MDD) in adults and is also FDA-cleared for Obsessive-Compulsive Disorder (OCD) and depression in adolescents. The company generates revenue from system sales, consumables, service contracts, and Greenbrook TMS Inc. treatment centers, which offer NeuroStar and SPRAVATO® for treatment-resistant depression.

Neuronetics, Inc. has operations in the United States and internationally, focusing on expanding its market presence in regions with unmet mental health treatment needs. The company has established a significant market presence by partnering with healthcare institutions and private practices across the United States.

Neuronetics, Inc. has a strong brand reputation, primarily through its NeuroStar Advanced Therapy System, which is recognized as the market leader in Transcranial Magnetic Stimulation (TMS) for the treatment of Major Depressive Disorder and other mental health conditions. The NeuroStar system is the #1 TMS choice among doctors, with over 6.4 million treatments performed to date. Recent events that have positively affected its reputation include the FDA clearance for NeuroStar as a first-line add-on for adolescents and the acquisition of Greenbrook TMS centers.

Neuronetics, Inc. has a diverse ownership structure that includes institutional, insider, and retail investors. Major institutional shareholders include Vanguard Group Inc and BlackRock, Inc., holding approximately 19.49% to 53.59% of the company's stock. Significant individual and insider owners include Cannell Capital LLC and Madryn Asset Management LP, holding approximately 8.70% to 32.73% of the stock. Retail investors own a substantial portion, estimated to be around 32% to 67.95% of the company.